Hans Ludwig Bock

Learn More
In low-income countries, infectious diseases still account for a large proportion of deaths, highlighting health inequities largely caused by economic differences. Vaccination can cut health-care costs and reduce these inequities. Disease control, elimination or eradication can save billions of US dollars for communities and countries. Vaccines have lowered(More)
Although pertussis in adults is well documented, opinions differ about incidence of adult disease and about the role of adults as reservoirs of infection. We made use of a prospective household contact study of an acellular pertussis vaccine to collect data about pertussis in adults. All members of families with an index case of pertussis were monitored for(More)
AIM India has the highest number of annual incident cases and mortality rates for cervical cancer worldwide. This study was conducted to assess the immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women aged 18-35 years old. METHODS This double-blind, randomized (1:1), controlled and(More)
This study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N=5,359) or placebo (N=5,349). From 2 weeks post-dose 2 to 2(More)
INTRODUCTION The world's first rotavirus vaccine, Rotashield or RRV-TV, was registered in the US in 1998, but withdrawn within a year because of an observed association with intussusception (IS). Surveillance for IS has consequently become important in safety monitoring of new-generation rotavirus vaccines during development. Post-marketing surveillance is(More)
The immunogenicity and lot-to-lot consistency of an AS03-adjuvanted H5N1 vaccine were evaluated in 1206 Asian adults, randomised to receive two doses of adjuvanted (3.75 microg haemagglutinin) or diluent-mixed vaccines, 21 days apart. Post-Dose 2, 96.0% of vaccinees in the H5N1-AS03 group demonstrated a four-fold increase in neutralising antibody titres(More)
OBJECTIVE To assess the immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in Chinese women aged 18 to 35 years enrolled from Hong Kong. DESIGN Double-blind, randomised controlled trial with vaccine and placebo groups. SETTING Single-centre study in Hong Kong. PARTICIPANTS Three hundred women enrolled (150(More)
Booster vaccination against hepatitis B (HBV) is not currently recommended, although debate continues on the duration of protection after priming. We assessed antibody persistence and immune memory to hepatitis B 20 years after priming with a recombinant HBV-vaccine during infancy. Infants were vaccinated at birth, 1, 2 and 12 months of age. A subset(More)
OBJECTIVE The aim of this cross-sectional study was to evaluate the prevalence of hepatitis B 'e' antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in pregnant women in the Gulf States. METHODS A total of 1710 pregnant women aged 15-45 years were enrolled in June-July 2000 in nine centres across Oman, Qatar and Unite Arab Emirates. The percentage of(More)
In a prospective multicentre trial, the influence of schedule, compliance, age, sex and weight on the antibody response to hepatitis B vaccination was investigated. Comparison of the vaccination schedules 0, 1, 6 months (group 1; n=143) and 0, 1, 2, 12 months (group 2; n=141) was performed in months 3, 7 and 12. In addition, the antibody response was(More)